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Summary
Lamina-associated polypeptide 2 alpha (LAP2a) plays a role in
maintaining nuclear structure, in nuclear assembly/disassembly,
and in transcriptional regulation. Elevated LAP2a mRNA expres-
sion has been previously reported to associate with certain cancer
types. The aim of this study was to investigate LAP2a expression
in cervical cancer and transformed cells and to identify factors
that associate with its differential expression. LAP2a expression
was found to be elevated in cervical cancer tissue by microarray,
qRT-PCR, and immunofluorescence analyses. LAP2a also showed
elevated expression in cervical cancer cell lines and in transformed
fibroblasts compared with normal cells. To determine factors asso-
ciated with elevated LAP2a in cervical cancer, the effect of inhibi-
ting HPV E7 and E6 oncoproteins was investigated. E7 inhibition
resulted in a decrease in phosphorylated Rb and an associated
decrease in LAP2a, suggesting a role for E2F in regulating LAP2a
expression. This finding was confirmed by inhibiting DP1, a co-
activator of E2F, which resulted in decreased LAP2a levels. Inhi-
bition of E6 resulted in elevated p53 and an associated decrease in
LAP2a, suggesting that p53 associates with the negative regulation
of LAP2a expression. This hypothesis was tested by inhibiting
p53 in normal cells, and a resultant increase in LAP2a expression
was observed. In conclusion, this study provides evidence for
elevated LAP2a expression in cervical cancer and suggests that
E2F and p53 activities associate with the positive and negative
regulation of LAP2a expression, respectively.  2011 IUBMB
IUBMBLife, 00: 000–000, 2011
Keywords cervical cancer; lamina-associated polypeptide 2 alpha;
E2F; p53.
INTRODUCTION
Cervical cancer is the second most common form of cancer
in women worldwide (1). Between 90% and 100% of cervical
cancer cases are caused by infection with the human papilloma-
virus (HPV) (2), whereby high levels of viral-encoded oncopro-
teins, E6 and E7, trigger cancer development by binding to and
inactivating the growth regulatory proteins, p53, and retinoblas-
toma (Rb), respectively (reviewed in Ref. 2). This leads to
global changes in gene expression and ultimately causes cellular
transformation, which can result in the development of cervical
cancer. In order for alterations in gene expression in the cancer
state to be studied, we performed expression profiling of normal
and cervical cancer tissue. cDNA microarray analysis revealed
a significant upregulation of the nuclear structural protein, Lam-
ina-associated polypeptide 2 alpha (LAP2a), in cervical cancer
tissue compared with normal.
LAP2a is a member of the LAP family of nuclear proteins
and encoded by the LAP2 gene. There are six different LAP2
isoforms (LAP2-a , b, c, d, e, f) encoded by LAP2, which are
alternatively spliced to produce proteins of differing molecular
weights (3, 4). The different LAP2 isoforms share a common
N-terminal region, and the alpha isoform contains a unique C-
terminal tail that lacks transmembrane regions (3). This makes
LAP2a nonmembrane bound and essentially nucleoplasmic,
localizing to the interior of the nucleus unlike its b, c, d, and e
counterparts that contain a transmembrane domain and are thus
anchored in the inner nuclear membrane (5, 6). The function of
LAP2a is still being elucidated, but evidence so far has shown
that it plays a role in maintaining nuclear architecture through
interacting with A-type lamins (7); it facilitates postmitotic nu-
clear assembly through interacting with chromosomes (8), and
it is involved in regulating transcriptional activity through
anchoring hypophosphorylated Rb in the nucleus (9). Addition-
ally, it has recently been shown that LAP2a associates with the
heat shock protein, Hsp70, suggesting that it could play a role
in resistance against stress (10).
LAP2a expression has been previously found to associate
with cell growth, as in a study by Markiewicz et al. (2002),
negligible LAP2a expression was observed in quiescent fibro-
blasts; however, its expression increased substantially once cells
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were induced to re-enter the cell cycle (9). Furthermore, LAP2a
expression was also found to decrease progressively in confluent
and postconfluent cultures, co-inciding with entry into G0 (11).
These findings imply that LAP2a expression is regulated in a
cell cycle-dependent manner, pointing to its potential deregula-
tion in cancer. In line with this, LAP2a expression has been
previously shown to be elevated in medulloblastoma (12) and
larynx, lung, stomach, breast, and colon primary tumors,
although only at the mRNA level (13). However, LAP2a
expression has not been previously determined in cervical can-
cer material nor has its protein expression been evaluated in
any tumor tissue to date. The aim of this study was, therefore,
to confirm our microarray study showing increased LAP2a
mRNA expression in cervical cancer, to determine its expres-
sion at the protein level, and to investigate the molecular mech-




Patient material was collected from Groote Schuur Hospital,
Cape Town, South Africa. Cancer tissue was collected from
patients with cervical carcinoma, and ‘‘normal’’ tissue from
patients admitted for hysterectomies for reasons other than cer-
vical abnormalities. A pathologist confirmed normal or diseased
status. Samples were obtained with patient consent, and the
study was approved by the Research Ethics Committee of the
University of Cape Town (REC REF:153/2004) (14).
RNA Isolation and Microarray Analysis
Total RNA from patient tissue was isolated using Trizol
reagent (Invitrogen) and amplified using the Eberwine RNA
amplification procedure (15), as described previously (16).
Human reference RNA (Stratagene) served as a control. Microar-
ray analysis was performed using 11,000-element cDNA micro-
array slides produced by the Microarray Core Facility, National
Cancer Institute, USA, using Incyte Genomics UniGEM clones,
as described (14). Normal and cancer group comparisons were
performed in MaDB (17) using a multivariate permutation test.
Immunohistochemistry of Patient Tissue Sections
Normal and cancer tissue sections were obtained from
archived paraffin-embedded sections and heat-fixed prior to re-
hydration and de-waxing. Antigen retrieval was performed by
pressure-cooking in EDTA, pH 8.0, and slides blocked in 0.2%
gelatin. LAP2a specific antibody (5162; Abcam) was added at
1:100 for 1 H in a humidified chamber at RT. Slides were
washed and incubated in 0.3% Sudan Black before a Cy3-con-
jugated goat antirabbit secondary antibody (Jackson ImmunoRe-
search) was added at 1:300 and incubated for 45 Min. Slides
were incubated with DAPI (Sigma), mounted in Mowiol 4-88
(Calbiochem), and visualized on a Zeiss fluorescent microscope.
Table 1
Genes up-regulated in cervical cancer tissue compared with normal cervix (P\ 0.0005)
Gene Description Fold change P-value
KPNA2 Karyopherin alpha 2 (RAG cohort 1, importin alpha 1) 4.4 7.80E-09
CCT5 Chaperonin containing TCP1, subunit 5 (epsilon) 3.5 2.20E-06
MTHFD2 Methylenetetrahydrofolate dehydrogenase 2 3.4 2.80E-04
RAN RAN, member RAS oncogene family 3 2.10E-06
SNRPB Small nuclear ribonucleoprotein polypeptides B and B1 2.9 5.80E-06
HDGF Hepatoma-derived growth factor (high-mobility group protein 1-like) 2.8 5.50E-05
heat shock 60kD protein 1 (chaperonin) 2.7 8.70E-05
SLC25A5 Solute carrier family 25 (mitochondrial carrier) 2.7 1.40E-04
PCNA Proliferating cell nuclear antigen 2.6 8.40E-07
STMN1 Stathmin 1/oncoprotein 18 2.6 7.50E-07
TMPO Thymopoietin/LAP2a 2.6 2.90E-04
TPM3 Tropomyosin 3 2.5 2.40E-09
THBS2 Thrombospondin 2 2.5 4.70E-05
ITGB1 Integrin, beta 1 2.4 4.00E-04
HSP90B1 Heat shock protein 90kDa beta (Grp94), member 1 2.4 6.50E-05
protocadherin alpha 9 2.4 3.70E-07
PSMD11 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 2.3 2.40E-05
LDHA Lactate dehydrogenase A 2.3 4.40E-04
H2AFZ H2A histone family, member Z 2.3 2.10E-05
PKM2 Pyruvate kinase, muscle 2.3 2.70E-05
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Images were viewed using Axiovision 4.6 software, and fluores-
cence intensity quantitated using six fields of view per slide.
Cell Lines and Cell Culture
Cell lines used included: normal primary cervical epithelial
cell culture, HCX, its transformed counterpart, HCX-E6/E7 (Dr.
C. Baker, NIH, USA (18)), cervical cancer cell lines, CaSki,
HeLa, ME-180, MS751, SiHa and C33A (American Type Cul-
ture Collection (ATCC)), normal lung fibroblasts, WI38, trans-
formed SVWI38 and CT-1 (19), normal breast skin fibroblasts,
CCD1068SK, and normal skin fibroblasts, FG0 (UCT). SVWI38
fibroblasts are WI38 cells that were transformed using the SV40
virus (20), while CT-1 fibroblasts are WI38 cells that were
transformed by gamma irradiation (19). All cell lines were
maintained in DMEM supplemented with 10% foetal calf serum
(Gibco) and 100 units/mL penicillin and 100 lg/mL streptomy-
cin, with the exception of HCX and HCX-E6/E7, which were
maintained in keratinocyte serum-free medium (Invitrogen),
containing 50 lg/mL bovine pituitary extract, 26 ng/mL epider-
mal growth factor, and penicillin and streptomycin. HCX-E6/E7
cells were grown in the presence of 50 lg/mL G418. All cells
were kept at 37 8C in a 5% CO2 incubator.
Real-Time RT-PCR
qRT-PCR was performed using primers specific for LAP2a:
F 50-GCAGGCAGACATTAGTCAAGC-30, R 50-CGACCTA-
CAGTGGCATTTCC-30; p53: F 50-CAACAAGATGTTTTGC-
CAACTG-30, R 50-ATGTGCTGTGACTGCTTGTAGATG-30;
CyclophilinD: F 50-TGAGACAGCAGATAGAGCCAAGC-30, R
50-TCCCTGCCAATTTGACATCTTC-30; and b-glucuronidase:
F 50-CTCATTTGGAATTTTGCCGATT-30, R 50-CCGAGT-
GAAGATCCCCTTTTTA-30. qRT-PCR was performed using
KAPA SYBR qPCR Master Mix (KAPA Biosystems) and the
StepOne Real-Time PCR machine (Applied Biosystems). The
DDCT method was used to calculate gene expression relative to
that of the average of cyclophilin D and b-glucuronidase (21).
Immunofluorecence of Cultured Cells
Cells were plated on coverslips, grown to 80% confluency,
and fixed in 4% paraformaldehyde. Fixed cells were incubated
in 0.1% Triton X-100 in PBS followed by 50 mM NH4Cl in
PBS and blocked in 0.2% gelatin. Cells were subsequently incu-
bated with 1:100 LAP2a primary antibody (5162; Abcam) for
45 Min in a humidified chamber. After washing in PBS, 1:300
Cy3-conjugated goat antirabbit secondary antibody (Jackson
ImmunoResearch) was applied for a further 45 min. Cell nuclei
were stained with 100 ng/mL DAPI and coverslips mounted in
Mowiol.
RNA Interference
Cells were transfected with 20 nM LAP2 siRNA (sc-43386),
DP1 siRNA (sc-37813), p53 siRNA (sc-29435), or Control
Table 2
Genes down-regulated in cervical cancer tissue compared with normal cervix (P\ 0.0005)
Gene Description Fold change P-value
Vimentin 0.4 3.90E-04
AHSG Alpha-2-HS-glycoprotein 0.6 2.50E-05
CXCL3 Chemokine (C-X-C motif) ligand 3 0.7 6.10E-06
ARID4A AT rich interactive domain 4A (RBP1-like) 0.7 6.20E-05
C16orf52 Chromosome 16 open reading frame 52 0.7 5.60E-05
B3GNTL1 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase-like 1 0.7 3.50E-04
RND2 Rho family GTPase 2 0.7 4.20E-04
CCL7 Chemokine (C-C motif) ligand 7 0.7 1.90E-04
TNFSF13 Tumor necrosis factor (ligand) superfamily, member 13 0.7 3.50E-04
PER2 Period homolog 2 (Drosophila) 0.7 2.60E-04
SLITRK2 SLIT and NTRK-like family, member 2 0.7 3.80E-05
S100A4 S100 calcium binding protein A4 0.7 4.20E-04
bromodomain adjacent to zinc finger domain, 1B 0.7 4.40E-04
GRIP2 Glutamate receptor interacting protein 2 0.7 1.40E-04
NSMAF Neutral sphingomyelinase (N-SMase) activation associated factor 0.7 2.80E-04
TSPAN8 Tetraspanin 8 0.7 2.90E-05
SLC1A1 Solute carrier family 1 0.8 7.20E-05
SURF5 Surfeit 5 0.8 4.60E-05
TUBGCP2 Tubulin, gamma complex associated protein 2 0.8 4.20E-04
PDCD11 Programmed cell death 11 0.8 3.20E-04
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Figure 1. Relative LAP2a mRNA and protein levels in normal and cervical cancer tissues. (A) A heat map view of the expression
patterns of down- or up-regulated genes in the cancer specimens compared with the normal specimens (green: low expression, red;
high expression). (B, C.) LAP2a mRNA expression determined by (A) microarray analysis (normal: n 5 8, cancer: n 5 16, *P \
0.0001) and (B) real-time RT-PCR analysis (normal: n 5 9, cancer: n 5 16, *P \ 0.05). b-glucuronidase and cyclophilin D were
used as normalizers of the real-time PCR data. Results shown for both microarray and real-time RT-PCR analyses represent the
mean 6 standard error of the mean (SEM). (D) Immunofluorescence showing LAP2a protein expression in representative normal
and cervical cancer tissue sections (4003 magnification). (E: epithelium; S: stroma) (E) Quantification of LAP2a protein expression
in normal and cancer tissue sections (normal: n 5 9, cancer: n 5 16, *P\ 0.05). Box and whisker plots were generated in Graph-
pad Prism and represent the mean 6 minimum and maximum values. [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
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siRNA-A (sc-37007) (Santa Cruz Biotechnology), using Trans-
Fectin lipid reagent (Bio-Rad). HPV16 E6 and E7 siRNAs were
designed as described in Ref. (22). RNA oligos were synthe-
sized by Ella Biotech GmBH (Germany) and annealed in a
reaction containing 30 lL each RNA oligo (50 lM) and 15 lL
annealing buffer (100 mM potassium acetate, 30 mM Hepes,
pH 7.4, 2 mM magnesium acetate) at 90 8C for 1 Min, followed
by 37 8C for 1 H, to give a 20 lM siRNA concentration. Cells
were transfected with 20 nM E6 siRNA or E7 siRNA.
Western Blot Analysis
Protein was harvested in RIPA buffer (10 mM Tris–Cl, pH
7.4, 150 mM NaCl, 1% sodium deoxycholate, 0.1% SDS, 1%
Triton X-100, 1X complete protease inhibitor cocktail (Roche)
and 1 mM Na3VO4 phosphatase inhibitor). Western blots were
performed using antibodies against LAP2 (sc-28541, Santa Cruz
Biotechnology), HPV16 E7 (sc-6981, Santa Cruz Biotechnol-
ogy), phospho-RB (ser 807/811) (#9308S, Cell Signaling),
p53 (M7001, DakoCytomation), p21 (sc-756, Santa Cruz
Figure 2. LAP2a protein expression in cultured cell lines. Western blot analysis showing LAP2a and LAP2b expression in (A) cer-
vical cancer cells (C33A, CaSki, HeLa ME-180, MS751, SiHa) compared with normal cervical epithelial cells, HCX, and HCX-
E6/E7-transformed cells; and (B) transformed lung fibroblasts (CT-1 and SVWI38) compared with normal fibroblasts (CCD1068SK
(breast), FG0 (skin), and WI38 (lung)). b-tubulin was used to control for protein loading. (C) Immunofluorescence showing LAP2a
expression in WI38, SVWI38 and CaSki cells, using a LAP2a specific antibody. (D) Quantification of LAP2a fluorescence obtained
from at least 100 cells per cell line, *P \ 0.05. Experiments were performed at least two independent times. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Biotechnology), DP1 (sc-610, Santa Cruz Biotechnology), and
b-tubulin (sc-9104, Santa Cruz Biotechnology).
RESULTS
Differential LAP2a mRNA and Protein Expression in
Normal and Cervical Cancer Patient Specimens
To identify genes with differential expression patterns in cer-
vical cancer and normal tissue cDNA, microarrays were per-
formed using RNA derived from eight normal and 16 cervical
cancer tissue specimens. Many genes were identified to have
either up- or down-regulated expression in cervical cancer tissue
compared with normal (Tables 1 and 2, Fig. 1A), and among
the genes identified to have significantly enhanced levels of
expression in the cancer samples was LAP2a, also known as
Thymopoietin (TMPO) (Table 1 and Fig. 1B). To confirm
increased LAP2a expression in the cancer specimens, real-time
RT-PCR was performed using RNA from 16 cervical cancer
and nine normal biopsy specimens. Results showed that LAP2a
expression was significantly increased in the cervical cancer
patient material compared with normal, validating the microar-
ray data (Fig. 1C).
Having established that cervical cancer tissue displays ele-
vated LAP2a mRNA, immunofluorescence was next used to
assay LAP2a protein expression in archival patient tissue sec-
tions. High LAP2a expression was detected in the cervical can-
cer cells, and its expression was evident compared with that in
the surrounding stromal tissue, which showed little staining
(Fig. 1D). In contrast, very low LAP2a expression was detected
within the epithelium of normal cervical tissue. Quantification
of LAP2a fluorescence intensity in 16 cancer and nine normal
tissue sections revealed a significant increase in LAP2a expres-
sion in the cancer specimens (Fig. 1E). These findings support
the microarray and real-time RT-PCR data, and together suggest
that enhanced LAP2a mRNA and protein expression associate
with cervical cancer.
LAP2a Protein Expression in Normal, Cervical Cancer,
and Transformed Cell Lines
To determine whether LAP2a expression is elevated in cer-
vical cancer cells grown in culture, its expression was deter-
mined in a panel of cervical cancer cell lines (C33A, CaSki,
HeLa, ME-180, MS751, and SiHa) and compared with that in
a normal primary cervical epithelial cell culture, HCX, and its
transformed counterpart HCX-E6/E7. Western blot analysis
revealed that LAP2a expression was elevated in all of the can-
cer cell lines compared with normal (Fig. 2A). As the anti-
body used for Western blot analysis recognizes the common
N-terminal region of the human LAP2 isoforms, LAP2b
expression was also detected in the cancer cells and found to
be elevated in the cervical cancer cell lines. Expression of
LAP2a and LAP2b was also increased in the HPV E6/E7-
transformed cell line compared with the normal HCX cells,
suggesting that expression of LAP2 may associate with cellu-
lar transformation.
To investigate the possibility that LAP2a expression associ-
ates with cellular transformation, its expression was determined
in normal (CCD1068SK, FG0, and WI38) and transformed
(SVWI38 and CT-1) fibroblasts. Western blots showed barely
detectable LAP2a in the normal fibroblasts, while the trans-
formed fibroblasts showed substantially higher levels of expres-
sion (Fig. 2B), again suggesting that elevated LAP2a expression
associates with cellular transformation. Similar results were
seen for LAP2b. The increase in LAP2a expression was inde-
pendently confirmed by immunocytochemistry, using a LAP2a-
specific antibody, with transformed SVWI38 cells showing ele-
vated LAP2a expression compared with the untransformed
WI38 cells and comparable with that of the cervical cancer cell
Figure 3. LAP2a expression associates with E2F. (A) Western
blot analysis showing E7, phospho-RB, and p53 levels in
response to E7 inhibition using 20 nM E7 siRNA. To control
for the nonspecific effects of siRNA transfection, 20 nM control
(ctl) siRNA was used. (B) Western blots showing decreased
LAP2a expression within 24 H of E7 inhibition. Lower panel:
A longer exposure of the Western blot, showing LAP2a expres-
sion in response to E7 siRNA treatment, reveals a time-depend-
ent decrease in LAP2a levels. (C) Western blots showing
decreased LAP2a expression after DP1 inhibition. b-tubulin was
used as a control for protein loading.
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line, CaSki (Fig. 2C). Quantification of the fluorescence showed
significantly higher LAP2a levels in the cancer and transformed
cells compared with the normal cells (Fig. 2D).
Elevated LAP2a Expression in Cervical Cancer Cells
Associates with Aberrant E2F/RB and p53 Activities
As we had observed high LAP2a expression in cervical
cancer, we next investigated the factors that could account for
its elevated expression. Previous studies in osteosarcoma cells
reported that LAP2a expression is regulated by members of
the E2F family (13). In cervical cancer, the HPV oncoproteins,
E6 and E7, bind to and block the functions of the tumor sup-
pressor proteins, p53 and RB, respectively. E6 binds p53, tar-
geting p53 for degradation (23). E7 binding to RB interferes
with the function of RB (24), where under normal circumstan-
ces, hypophosphorylated RB forms a complex with the tran-
scription factor E2F and inhibits E2F activity. The binding of
E7 to RB sequesters RB and causes its phosphorylation and
degradation, resulting in the untimely release of active E2F
(25). Hence, we postulated that inhibition of E7 in cervical
cancer cells would result in hypophosphorylated RB, which in
turn would inhibit E2F activity and affect LAP2a expression.
E7 siRNA was thus used to inhibit E7 expression in CaSki
cervical cancer cells, and a substantial reduction in phospho-
rylated RB was observed (Fig. 3A). E7 inhibition and hypo-
phosphorylated RB associated with a significant reduction in
LAP2a expression (Fig. 3B), likely as a result of the ability of
hypophosphorylated RB to bind and inhibit E2F activity. A
longer exposure of the Western blot showing LAP2a expres-
sion in response to E7 siRNA treatment reveals a time-de-
pendent decrease in LAP2a levels (Fig. 3B, lower panel). To
investigate the requirement of E2F for high LAP2a expression
in cervical cancer, the activity of the E2F proteins was inhib-
ited, by silencing the expression of DP1, a co-activator essen-
tial for E2F function. Inhibition of DP1 resulted in a reduction
in LAP2a expression within 24 H of DP1 siRNA transfection
(Fig. 3C). These results suggest that high E2F activity is
required for the elevated levels of LAP2a observed in cervical
cancer cells. We also observed an increase in the levels of
p53 after inhibition of E7 in cervical cancer cells (Fig. 3A),
suggesting an involvement of wildtype p53 in the regulation
of LAP2a, as increasing p53 levels associated with a decrease
in expression of LAP2a.
To investigate a possible role for p53 in regulating LAP2a
expression, the expression of HPV E6, the negative regulator
Figure 4. LAP2a expression associates with p53 expression. (A) Western blot analysis showing an increase in p53 levels in CaSki
cell lysates after E6 inhibition. (B) Western blots showing decreased LAP2a expression after E6 siRNA transfection. (C,D) Real-
time RT-PCR data showing (C) p53 and (D) LAP2a mRNA expression in WI38 cells transfected with p53 siRNA (*P\ 0.05). (E)
Western blot analysis showing LAP2a protein expression in p53 inhibited cells. p21 levels decreased confirming the inhibition of
p53 activity. b-tubulin was used as a control for protein loading.
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of p53 in cervical cancer, was inhibited using siRNA. E6 inhi-
bition resulted in elevated p53 levels (Fig. 4A) and was shown
to associate with a significant decrease in expression of
LAP2a (Fig. 4B), suggesting that p53 might play a role sup-
pressing LAP2a expression under normal conditions. To test
this hypothesis, p53 expression was inhibited in normal WI38
cells, containing wildtype p53 and low LAP2a expression. p53
inhibition using siRNA (Fig. 4C) resulted in an increase in
both LAP2a mRNA and protein expression (Figs. 4D and 4E).
To confirm interference with p53 activity, the expression of
p21, a downstream target of p53, was determined, and a
decrease in p21 was observed in p53 siRNA transfected cells
(Fig. 4E).
DISCUSSION
This study provides evidence for elevated LAP2a mRNA
and protein expression in cervical cancer and describes an asso-
ciation of E2F and p53 with its expression in cervical cancer
cells. We also show that expression of LAP2a is increased in
transformed cells in culture compared with their untransformed
counterparts, suggesting that LAP2a overexpression is likely a
feature of the transformed phenotype.
LAP2a has been previously reported to be regulated by E2F
in osteosarcoma cells through the binding of E2F to the LAP2
promoter (13), and our results support of a role for E2F in regu-
lating LAP2a expression in cervical cancer cells. Interestingly,
LAP2a plays a role in the negative regulation of E2F activity,
as it has been found to anchor hypophosphorylated Rb in the
nucleus, and this in turn enhances Rb stability and Rb silencing
activity, resulting in the decreased activation of E2F target
genes (9, 26). Hence, it appears that LAP2a and E2F relate in
the form of a negative feedback loop. We propose that in cervi-
cal cancer, however, where Rb is inactivated by the HPV E7
protein, it is likely that the feedback loop is broken, hence con-
tributing to deregulated LAP2a expression.
In line with this, we show that LAP2a levels decrease when
HPV E7 is inhibited. Published reports show that after inhibition
of E7 in CaSki cervical cancer cells, the cells undergo a G1 arrest
and accumulate hypophosphorylated RB (27). Based on RB func-
tion, hypophosphorylated RB results in a subsequent inhibition of
E2F and we postulate that this causes the decrease in LAP2a
expression. However, it is difficult to distinguish whether the
changes in LAP2a expression upon E7 inhibition are due to the
fact that E2F function is inhibited or, alternatively, due to cell
cycle arrest (via an E2F-independent manner).
Our results are a first to suggest a potential role for p53 in the
negative regulation of LAP2a expression. As cancer cells com-
monly contain mutations in the p53 gene (28), it is likely that this
contributes to the deregulation of LAP2a expression observed in
several cancer types (12, 13). We show that inhibition of p53
affects LAP2a at the mRNA and protein levels. Whether p53
directly or indirectly regulates LAP2a at the promoter level is
unclear at present, and future work is required to address this.
Together, the findings presented in this study suggest that
the growth regulatory proteins, E2F and p53, associate with the
positive and negative regulation of LAP2a expression, respec-
tively. We propose that activation of E2F and inactivation of
p53 by HPV E7 and E6 proteins, respectively, are key contribu-
tors to LAP2a overexpression in cervical cancer. The functional
significance of LAP2a overexpression in cancer, however,
remains to be elucidated, and the contradictory reports in litera-
ture regarding its potential role in cell proliferation highlight
the need for further work (11, 26, 29).
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